title: Prescription of calcium concentration and PTH control.
abstract: The use of calcium-containing oral phosphate binders, introduced in an effort to avoid aluminum-containing compounds, had led to more frequent episodes of hypercalcemia. This prompted the introduction of continuous ambulatory peritoneal dialysis (CAPD) solutions with diminished calcium content. The problems raised by such solutions included stimulation of parathyroid hormone (PTH) secretion and long-term maintenance of calcium balance. Some of these issues can today be answered on the basis of controlled prospective trials. Variability of the rate of intestinal calcium uptake of bone turnover, of baseline parathyroid activity, and other factors make it necessary to individualize the indication for the use of CAPD solutions with low calcium content.
authors.affiliation: Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Ritz
authors.forename: J
authors.initials: J
authors.lastname: Passlick-Deetjen
authors.forename: M
authors.initials: M
authors.lastname: Zeier
authors.forename: A
authors.initials: A
authors.lastname: Stefanski
mesh_terms: D002118:Calcium / Q000008:administration & dosage* / Q000097:blood; D002352:Carrier Proteins / Q000008:administration & dosage / Q000502:physiology; D015314:Dialysis Solutions / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000628:therapy*; D010281:Parathyroid Hormone / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000503:physiopathology; D028044:Phosphate-Binding Proteins
chemical_list: D002352:Carrier Proteins; D015314:Dialysis Solutions; D010281:Parathyroid Hormone; D028044:Phosphate-Binding Proteins; D002118:Calcium